Servier is acquiring Edgewise Therapeutics’ muscular dystrophy business, stepping into neurology and muscular dystrophy with a deal structured around an upfront cash payment and performance milestones. The acquisition centers on Edgewise’s fast skeletal myosin inhibitor sevasemten (EDG-5506), according to deal reporting. The transaction is positioned as part of Servier’s revenue growth strategy and aims to leverage clinical-readiness momentum in rare neuromuscular disorders, where treatment options are limited. Edgewise is expected to provide pivotal-trial and late-stage data pathways for Becker muscular dystrophy and Phase 2 development in Duchenne muscular dystrophy. From a sector perspective, the deal underscores continuing appetite for late-stage rare-disease assets with clear differentiation and timelines for pivotal readouts. It also adds pressure on other neuromuscular developers to show durable efficacy signals in skeletal muscle functional endpoints.